Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health & Substan...
November 09 2017 - 7:00AM
Business Wire
— ALKERMES INSPIRATION GRANTS® Program Awards
$1 Million to Non-Profit Organizations for the Development or
Expansion of Innovative Programs —
Alkermes plc (NASDAQ: ALKS) today announced the company awarded
$1 million in grants to national and local non-profit community
organizations for the implementation of innovative, high-impact and
replicable programs designed to support people affected by mental
health and substance use disorders. Now in its second year,
ALKERMES INSPIRATION GRANTS® focuses on two key areas: improving or
enhancing support or resources for people affected by mental health
concerns or substance use disorder, and/or integrating the
perspective of people affected by mental health concerns or
addiction into drug development or care delivery.
“Addiction and mental illness affect millions of people and
their families every day, and require an integrated approach to
treatment that is scalable in communities across the country,” said
Richard Pops, Chief Executive Officer of Alkermes. “Medicines play
a role, but importantly, it is the innovative programs designed to
support people affected by these diseases and led by passionate
leaders on the front lines that will ignite sustainable and
meaningful change for patients.”
Nearly 300 proposals were received from local, regional and
national non-profit organizations across the U.S. Thirteen grants
were awarded to programs demonstrating the potential for high
impact and an ability for sustainability and/or replication, and
innovative and creative approaches to support the broader needs of
people in the mental health and addiction communities. To view the
full list of recipients, please click here.
“We are again encouraged and inspired by the overwhelming number
of high quality applications to our grants program this year,” said
Nikki Levy, Vice President of Patient Engagement at Alkermes.
“These organizations are doing incredible work and help bring an
important perspective to what we do at Alkermes. We look forward to
seeing the lasting impact these organizations will have on
communities affected by serious mental illness and substance use
disorders.”
“Alkermes is on the leading edge of biopharmaceutical companies
who recognize that their role and commitment to support patients
and families extend beyond developing innovative medicines,” said
Kim McCleary, Managing Director at FasterCures. “Having served on
the review committee for two years now, the breadth of unmet needs
of people affected by mental health conditions and substance use
disorders is staggering, and the novel approaches to meeting those
needs at the grassroots level are inspiring. I applaud Alkermes for
prioritizing the support of these organizations and providing
funding to make innovative programs a reality. It’s a model for
meeting patients where they are and recognizing the totality of the
impact of disease on their lives and the lives of those around
them.”
Recipients were selected by an external and internal review
committee, including representatives from Alkermes, a patient
advocate, a representative from the criminal justice system, a
person in recovery and a caregiver. Proposals were evaluated based
on a standard set of review criteria, which included potential
impact, identification of need and creativity of the solution,
ability to execute, and sustainability of the program.
For more information on the ALKERMES INSPIRATION GRANTS program,
please visit www.alkermes.com/inspirationgrants.
About Alkermes
Alkermes plc is a fully integrated, global biopharmaceutical
company developing innovative medicines for the treatment of
central nervous system (CNS) diseases. The company has a
diversified commercial product portfolio and a substantial clinical
pipeline of product candidates for chronic diseases that include
schizophrenia, depression, addiction and multiple sclerosis.
Headquartered in Dublin, Ireland, Alkermes plc has an R&D
center in Waltham, Massachusetts; a research and manufacturing
facility in Athlone, Ireland; and a manufacturing facility in
Wilmington, Ohio. For more information, please visit Alkermes’
website at www.alkermes.com.
ALKERMES INSPIRATION GRANTS® is a registered service mark of
Alkermes, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171109005177/en/
Alkermes Contacts:For Investors:Eva
Stroynowski, +1 781-609-6823orSandy Coombs, +1 781-609-6377orFor
Media:Lindsey Smith, +1 781-609-6231
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Apr 2023 to Apr 2024